Compare GSK plc (GSK) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs WD 40 Company — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while WD 40 Company trades at $254.9 (market cap $3.35B). The key difference: GSK plc is far larger — about 30.3× WD 40 Company's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | WDFC | |
|---|---|---|
Market Cap | $101.34B | $3.35B |
Sector | Health | Technology |
52-Week High | $61.18 | $264.91 |
52-Week Low | $36.20 | $187.52 |
Enterprise Value | $121.95B | $3.40B |
Dividend Yield | 3.49% | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
WDFC trades at $257.99, up 3.56% with strong technical momentum showing bullish signals across moving averages and oscillators. The company delivered impressive Q2 2026 earnings of $2.33 per share, beating estimates by 47%, while maintaining solid profitability with 13.22% net margins. Recent news highlights WD-40's brand strength and consistent performance, with the stock appearing on Zacks' Strong Buy list on July 15, 2026.
The outlook remains positive given strong earnings momentum and brand dominance, though elevated valuation metrics (P/E 37.88) and margin pressure from rising costs present risks. Analyst consensus leans neutral with 71% hold ratings, suggesting cautious optimism about the company's steady growth trajectory amid competitive and inflationary challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
